Aqemia
PrivateLast Round
Grant
Apr 1, 2025
Total Funding Raised
$102.8M
Momentum Score
50 /100
Company Overview
Aqemia is a pharmatech company that utilizes a unique platform combining generative AI with quantum-inspired physics to accelerate drug discovery. Founded in 2019 as a spin-off from École Normale Supérieure in Paris, the company aims to design innovative small-molecule drugs for critical diseases, with an initial focus on oncology and immuno-oncology. Unlike many AI platforms that require extensive experimental data for training, Aqemia's technology generates its own data using physics-based algorithms to predict the affinity between molecules and therapeutic targets. This approach allows them to tackle drug discovery from the earliest stages and design novel drug candidates more rapidly. The company has secured significant funding, including a Series A round that reached €60 million and a total cumulative funding of over $100 million. Aqemia has established major collaborations with pharmaceutical companies like Sanofi and Servier and is advancing its own internal pipeline of drug candidates, with some projects reaching in-vivo testing.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, ML Platforms
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aqemia Comps
Public and private peers based on sector, stage, and business model.
Aqemia Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 1, 2025 | ||||
| Early Funding | Dec 10, 2024 | ||||
| Series A | Jan 30, 2024 | ||||
| Series A | Oct 19, 2022 | ||||
| Pre Seed | Oct 17, 2019 |
Key People
Founding team and executive leadership
Aqemia Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Wendel Growth | Series A |
| Elaia Partners | Series A, Early Funding |
| Bpifrance | Series A |
| Wendel Group | Early Funding |
| Bpifrance | Series A |
| Eurazeo | Early Funding, Series A |
| Bpifrance Large Venture | Early Funding, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Recognized as a key player in Europe's DeepTech ecosystem.
- Apr 21, 2026
Recognized as a key player in Europe's DeepTech ecosystem.
Aqemia Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Aqemia's valuation, stock price, and market status.
